Genomic Health Inc. (NASDAQ:GHDX) traded up 4.7% during mid-day trading on Monday . The company traded as high as $30.57 and last traded at $30.38, with a volume of 78,457 shares. The stock had previously closed at $29.03.

A number of equities research analysts recently issued reports on the company. Canaccord Genuity reissued a “buy” rating on shares of Genomic Health in a research note on Thursday, May 5th. Zacks Investment Research upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Finally, Leerink Swann restated a “buy” rating on shares of Genomic Health in a report on Tuesday, June 21st. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Genomic Health has a consensus rating of “Hold” and a consensus price target of $33.50.

The company’s market cap is $1.00 billion. The stock’s 50-day moving average price is $26.95 and its 200 day moving average price is $26.86.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. The company earned $80.89 million during the quarter, compared to analysts’ expectations of $78.12 million. Genomic Health’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) earnings per share. Analysts anticipate that Genomic Health Inc. will post ($0.45) earnings per share for the current fiscal year.

In related news, insider Phillip G. Febbo sold 6,324 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $27.20, for a total value of $172,012.80. Following the transaction, the insider now directly owns 15,113 shares in the company, valued at $411,073.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steven Shak sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $25.43, for a total value of $254,300.00. Following the completion of the transaction, the insider now owns 336,383 shares in the company, valued at $8,554,219.69. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its position in Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock worth $1,012,000 after buying an additional 2,287 shares in the last quarter. California State Teachers Retirement System boosted its position in Genomic Health by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 32,989 shares of the company’s stock worth $1,161,000 after buying an additional 600 shares in the last quarter. Royce & Associates LLC boosted its position in Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock worth $2,341,000 after buying an additional 31,500 shares in the last quarter. Russell Frank Co boosted its position in Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock worth $3,517,000 after buying an additional 76,416 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in Genomic Health during the fourth quarter worth approximately $6,097,000.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.